{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:57:22Z","timestamp":1781308642859,"version":"3.54.1"},"reference-count":166,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute (NHLBI)","doi-asserted-by":"publisher","award":["1U01HL156620-01"],"award-info":[{"award-number":["1U01HL156620-01"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"name":"intramural research program of the NHLBI, National Institutes of Health","award":["1U01HL156620-01"],"award-info":[{"award-number":["1U01HL156620-01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The goal of curing children and adults with sickle cell disease (SCD) is to maximize benefits and minimize intermediate and long-term adverse outcomes so that individuals can live an average life span with a high quality of life. While greater than 2000 individuals with SCD have been treated with curative therapy, systematic studies have not been performed to evaluate the long-term health effects of hematopoietic stem cell transplant (HSCT) in this population. Individuals with SCD suffer progressive heart, lung, and kidney disease prior to curative therapy. In adults, these sequalae are associated with earlier death. In comparison, individuals who undergo HSCT for cancer are heavily pretreated with chemotherapy, resulting in potential acute and chronic heart, lung, and kidney disease. The long-term health effects on the heart, lung, and kidney for children and adults undergoing HSCT for cancer have been extensively investigated. These studies provide the best available data to extrapolate the possible late health effects after curative therapy for SCD. Future research is needed to evaluate whether HSCT abates, stabilizes, or exacerbates heart, lung, kidney, and other diseases in children and adults with SCD receiving myeloablative and non-myeloablative conditioning regimens for curative therapy.<\/jats:p>","DOI":"10.3390\/jcm11113118","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T09:24:29Z","timestamp":1653989069000},"page":"3118","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Long-Term Health Effects of Curative Therapies on Heart, Lungs, and Kidneys for Individuals with Sickle Cell Disease Compared to Those with Hematologic Malignancies"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5306-7167","authenticated-orcid":false,"given":"Courtney D.","family":"Fitzhugh","sequence":"first","affiliation":[{"name":"Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, NIH, Building 10, MSC 1589, Bethesda, MD 20814, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel J.","family":"Volanakis","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Vanderbilt-Meharry Center of Excellence in Sickle Cell Disease, Vanderbilt University Medical Center, 2525 West End Ave., Suite 750 VIGH, Nashville, TN 37203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombeni","family":"Idassi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Vanderbilt-Meharry Center of Excellence in Sickle Cell Disease, Vanderbilt University Medical Center, 2525 West End Ave., Suite 750 VIGH, Nashville, TN 37203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh A.","family":"Duberman","sequence":"additional","affiliation":[{"name":"Office of Research Services, Office of the Director, NIH Library, NIH, Building 10, MSC 1150, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0574-1604","authenticated-orcid":false,"given":"Michael R.","family":"DeBaun","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Vanderbilt-Meharry Center of Excellence in Sickle Cell Disease, Vanderbilt University Medical Center, 2525 West End Ave., Suite 750 VIGH, Nashville, TN 37203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra L.","family":"Friedman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, 395 Preston Research Building, 2220 Pierce Ave., Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","article-title":"Population Estimates of Sickle Cell Disease in the U.S","volume":"38","author":"Hassell","year":"2010","journal-title":"Am. J. Prev. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1182\/blood-2018-03-818161","article-title":"How I treat the older adult with sickle cell disease","volume":"132","author":"Thein","year":"2018","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ajh.21408","article-title":"The cost of health care for children and adults with sickle cell disease","volume":"84","author":"Kauf","year":"2009","journal-title":"Am. J. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2009-07-233700","article-title":"Improved survival of children and adolescents with sickle cell disease","volume":"115","author":"Quinn","year":"2010","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/bjh.14015","article-title":"Improvement of medical care in a cohort of newborns with sickle-cell disease in North Paris: Impact of national guidelines","volume":"173","author":"Couque","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3324\/haematol.10937","article-title":"Clinical outcomes in children with sickle cell disease living in England: A neonatal cohort in East London","volume":"92","author":"Telfer","year":"2007","journal-title":"Haematologica"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2018-10-880575","article-title":"Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: A pooled analysis","volume":"133","author":"DeBaun","year":"2019","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1477-7525-3-50","article-title":"Health related quality of life in sickle cell patients: The PiSCES project","volume":"3","author":"McClish","year":"2005","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Fitzhugh, C.D., Hsieh, M.M., Allen, D., Coles, W.A., Seamon, C., Ring, M., Zhao, X., Minniti, C.P., Rodgers, G.P., and Schechter, A.N. (2015). Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0141706"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/ajh.21569","article-title":"Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease","volume":"85","author":"Fitzhugh","year":"2009","journal-title":"Am. J. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in sickle cell disease. Life expectancy and risk factors for early death","volume":"330","author":"Platt","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"614","DOI":"10.7326\/0003-4819-115-8-614","article-title":"Chronic Renal Failure in Sickle Cell Disease: Risk Factors, Clinical Course, and Mortality","volume":"115","author":"Powars","year":"1991","journal-title":"Ann. Intern. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.md.0000189089.45003.52","article-title":"Outcome of sickle cell anemia: A 4-decade observational study of 1056 patients","volume":"84","author":"Powars","year":"2005","journal-title":"Medicine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/01.paf.0000257397.92466.50","article-title":"Sickle cell lung disease and sudden death: A retrospective\/prospective study of 21 autopsy cases and literature review","volume":"28","author":"Graham","year":"2007","journal-title":"Am. J. Forensic Med. Pathol."},{"key":"ref_15","first-page":"56","article-title":"Patterns of mortality in sickle cell disease in adults in France and England","volume":"3","author":"Perronne","year":"2002","journal-title":"Hematol. J. Off. J. Eur. Haematol. Assoc.\/EHA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.20685","article-title":"Circumstances of death in adult sickle cell disease patients","volume":"81","author":"Darbari","year":"2006","journal-title":"Am. J. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/003335491312800206","article-title":"Mortality Rates and Age at Death from Sickle Cell Disease: U.S., 1979\u20132005","volume":"128","author":"Lanzkron","year":"2013","journal-title":"Public Health Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1002\/ajh.25202","article-title":"Clustering of end-organ disease and earlier mortality in adults with sickle cell disease: A retrospective-prospective cohort study","volume":"93","author":"Chaturvedi","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bjh.12024","article-title":"High one year mortality in adults with sickle cell disease and end-stage renal disease","volume":"159","author":"McClellan","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1056\/NEJM198409203111207","article-title":"Bone-Marrow Transplantation in a Patient with Sickle-Cell Anemia","volume":"311","author":"Johnson","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2016-10-745711","article-title":"Sickle cell disease: An international survey of results of HLA-identical sibling hematopoietic stem cell transplantation","volume":"129","author":"Gluckman","year":"2017","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2014.7192","article-title":"Nonmyeloablative HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Phenotype","volume":"312","author":"Hsieh","year":"2014","journal-title":"JAMA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.bbmt.2015.08.036","article-title":"Nonmyeloablative Stem Cell Transplantation with Alemtuzumab\/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease","volume":"22","author":"Saraf","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjh.17311","article-title":"Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: Outcomes from three independent centres","volume":"192","author":"Alzahrani","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_25","first-page":"1197","article-title":"Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide Plus Thiotepa Improves Donor Engraftment in Patients with Sickle Cell Anemia: Results of an International Learning Collaborative","volume":"25","author":"Dhedin","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S2352-3026(19)30031-6","article-title":"Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: A prospective clinical trial","volume":"6","author":"Cooke","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.bbmt.2018.03.031","article-title":"Haploidentical Peripheral Blood Stem Cell Transplantation Demonstrates Stable Engraftment in Adults with Sickle Cell Disease","volume":"24","author":"Saraf","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene Therapy in a Patient with Sickle Cell Disease","volume":"376","author":"Ribeil","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2029392","article-title":"Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease","volume":"384","author":"Esrick","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 Gene Editing for Sickle Cell Disease and \u03b2-Thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.bbmt.2016.09.025","article-title":"National Institutes of Health Blood and Marrow Transplant Late Effects Initiative: The Healthcare Delivery Working Group Report","volume":"23","author":"Hashmi","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/bmt.2017.67","article-title":"Provision of long-term monitoring and late effects services following adult allogeneic haematopoietic stem cell transplant: A survey of UK NHS-based programmes","volume":"52","author":"Hamblin","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/bmt.2012.5","article-title":"Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation","volume":"47","author":"Majhail","year":"2012","journal-title":"Bone Marrow Transplant."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.bbmt.2016.01.023","article-title":"Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children\u2019s Oncology Group Report","volume":"22","author":"Chow","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1182\/blood-2017-03-725671","article-title":"How I monitor long-term and late effects after blood or marrow transplantation","volume":"130","author":"Bhatia","year":"2017","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.bbmt.2018.04.002","article-title":"Late Effects Screening Guidelines after Hematopoietic Cell Transplantation (HCT) for Hemoglobinopathy: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT","volume":"24","author":"Shenoy","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.bbmt.2017.01.009","article-title":"Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation","volume":"23","author":"Shenoy","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2009.25.6693","article-title":"Life Expectancy in Patients Surviving More Than 5 Years After Hematopoietic Cell Transplantation","volume":"28","author":"Martin","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1200\/JCO.2010.33.7212","article-title":"Long-Term Survival and Late Deaths After Allogeneic Hematopoietic Cell Transplantation","volume":"29","author":"Wingard","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/JBM.S206027","article-title":"Optimal Delivery of Follow-Up Care After Allogeneic Hematopoietic Stem-Cell Transplant: Improving Patient Outcomes with a Multidisciplinary Approach","volume":"11","author":"Giaccone","year":"2020","journal-title":"J. Blood Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1001\/jamaoncol.2021.3676","article-title":"Trends in Late Mortality and Life Expectancy After Allogeneic Blood or Marrow Transplantation Over 4 Decades","volume":"7","author":"Bhatia","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood-2009-06-229369","article-title":"Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: A report from the Bone Marrow Transplant Survivor Study","volume":"116","author":"Sun","year":"2010","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/cncr.28444","article-title":"Cardiovascular disease in survivors of hematopoietic cell transplantation","volume":"120","author":"Armenian","year":"2013","journal-title":"Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.blre.2019.03.003","article-title":"Hypertension in hematologic malignancies and hematopoietic cell transplantation: An emerging issue with the introduction of novel treatments","volume":"35","author":"Gavriilaki","year":"2019","journal-title":"Blood Rev."},{"key":"ref_45","first-page":"250","article-title":"Early Cardiac Toxicity Associated with Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation","volume":"3","author":"Mohty","year":"2021","journal-title":"Cardio Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-155-1-201107050-00004","article-title":"Cardiovascular Hospitalizations and Mortality Among Recipients of Hematopoietic Stem Cell Transplantation","volume":"155","author":"Chow","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.critrevonc.2015.11.007","article-title":"Cardiovascular disease following hematopoietic stem cell transplantation: Pathogenesis, detection, and the cardioprotective role of aerobic training","volume":"98","author":"Scott","year":"2015","journal-title":"Crit. Rev. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11912-019-0774-6","article-title":"Cardiac Complications in the Adult Bone Marrow Transplant Patient","volume":"21","author":"Tuzovic","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1200\/JCO.2008.17.7428","article-title":"Late Congestive Heart Failure After Hematopoietic Cell Transplantation","volume":"26","author":"Armenian","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.bbmt.2010.02.021","article-title":"Predictors of Late Cardiovascular Complications in Survivors of Hematopoietic Cell Transplantation","volume":"16","author":"Armenian","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11912-018-0719-5","article-title":"Long-term Effects of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients with Acute Lymphoblastic Leukemia","volume":"20","author":"Lawitschka","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e26600","DOI":"10.1002\/pbc.26600","article-title":"Cardiotoxicity and cardiomyopathy in children and young adult survivors of hematopoietic stem cell transplant","volume":"64","author":"Rotz","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bbmt.2016.08.019","article-title":"National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report","volume":"23","author":"Armenian","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.bbmt.2014.02.012","article-title":"Late Cardiovascular Complications after Hematopoietic Cell Transplantation","volume":"20","author":"Chow","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jcmg.2015.06.028","article-title":"Valvular Dysfunction in Lymphoma Survivors Treated with Autologous Stem Cell Transplantation","volume":"9","author":"Murbraech","year":"2016","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5599","DOI":"10.1182\/bloodadvances.2021004846","article-title":"Cardiac Toxicity after Matched Allogeneic Hematopoietic Cell Transplantation in the Post-Transplant Cyclophosphamide Era","volume":"5","author":"Yeh","year":"2021","journal-title":"Blood Adv."},{"key":"ref_57","first-page":"295","article-title":"Long-term outcome after allo-SCT: Close follow-up on a large cohort treated with myeloablative regimens","volume":"45","author":"Lau","year":"2009","journal-title":"Bone Marrow Transplant."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.bbmt.2009.05.010","article-title":"Hypertension and Diabetes Mellitus in Adult and Pediatric Survivors of Allogeneic Hematopoietic Cell Transplantation","volume":"15","author":"Majhail","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood-2006-05-022335","article-title":"Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: A report from the bone marrow transplantation survivor study","volume":"109","author":"Baker","year":"2006","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.bbmt.2016.05.007","article-title":"Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT","volume":"22","author":"DeFilipp","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41409-018-0337-8","article-title":"Long-term health outcomes in survivors of childhood AML treated with allogeneic HSCT: A NOPHO\u2013AML Study","volume":"54","author":"Wilhelmsson","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bmt.1705652","article-title":"Impact of cumulative anthracycline dose, preparative regimen and chronic graft-versus-host disease on pulmonary and cardiac function in children 5 years after allogeneic hematopoietic stem cell transplantation: A prospective evaluation on behalf of the EBMT Pediatric Diseases and Late Effects Working Parties","volume":"39","author":"Uderzo","year":"2007","journal-title":"Bone Marrow Transplant."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1182\/blood-2011-06-358226","article-title":"Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation","volume":"118","author":"Armenian","year":"2011","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/CRD.0000000000000030","article-title":"Cardio-Oncology Issues Among Pediatric Cancer and Stem Cell Transplant Survivors","volume":"22","author":"Hochberg","year":"2014","journal-title":"Cardiol. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/bjh.12516","article-title":"Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation","volume":"163","author":"Armenian","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2013.52.6582","article-title":"Influence of Conventional Cardiovascular Risk Factors and Lifestyle Characteristics on Cardiovascular Disease After Hematopoietic Cell Transplantation","volume":"32","author":"Chow","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.bbmt.2017.06.004","article-title":"A Multicenter Retrospective Analysis Stressing the Importance of Long-Term Follow-Up after Hematopoietic Cell Transplantation for \u03b2-Thalassemia","volume":"23","author":"Chaudhury","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3324\/haematol.13514","article-title":"Cardiovascular disease after hematopoietic cell transplantation-lessons learned","volume":"93","author":"Armenian","year":"2008","journal-title":"Haematologica"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2141.2008.07165.x","article-title":"Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation","volume":"142","author":"Tichelli","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3324\/haematol.12949","article-title":"Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: A retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation","volume":"93","author":"Tichelli","year":"2008","journal-title":"Haematologica"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1182\/blood-2006-10-054080","article-title":"Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation","volume":"110","author":"Tichelli","year":"2007","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.bbmt.2014.09.010","article-title":"High-Dose Total Body Irradiation and Myeloablative Conditioning before Allogeneic Hematopoietic Cell Transplantation: Time to Rethink?","volume":"21","author":"Mohty","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.bbmt.2008.08.015","article-title":"Successful Outcome after Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Renal Dysfunction","volume":"14","author":"Kersting","year":"2008","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1182\/blood-2012-06-437178","article-title":"Cardiovascular risk factors in hematopoietic cell transplantation survivors: Role in development of subsequent cardiovascular disease","volume":"120","author":"Armenian","year":"2012","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00431-002-0961-5","article-title":"Pulmonary arterial occlusive disease following chemotherapy and bone marrow transplantation for leukaemia","volume":"161","author":"Vaksmann","year":"2002","journal-title":"Eur. J. Pediatr."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000091638","article-title":"Pulmonary Arterial Hypertension after Childhood Cancer Therapy and Bone Marrow Transplantation","volume":"105","author":"Limsuwan","year":"2006","journal-title":"Cardiology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00043426-200406000-00013","article-title":"Pulmonary Hypertension Complicating Bone Marrow Transplantation for Idiopathic Myelofibrosis","volume":"26","author":"Shankar","year":"2004","journal-title":"J. Pediatr. Hematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/20458940211027791","article-title":"Successful treatment of pulmonary hypertension following hematopoietic stem cell transplant with a single oral tadalafil: A case report","volume":"11","author":"Tanaka","year":"2021","journal-title":"Pulm. Circ."},{"key":"ref_79","first-page":"63","article-title":"Pulmonary Complications of Childhood Cancer Treatment","volume":"17","author":"Versluys","year":"2015","journal-title":"Paediatr. Respir. Rev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.prrv.2010.01.006","article-title":"Lung Function and Late Pulmonary Complications Among Survivors of Hematopoietic Stem Cell Transplantation During Childhood","volume":"11","author":"Gower","year":"2010","journal-title":"Paediatr. Respir. Rev."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1513\/AnnalsATS.202001-006OT","article-title":"Pulmonary Complications of Pediatric Hematopoietic Cell Transplantation. A National Institutes of Health Workshop Summary","volume":"18","author":"Tamburro","year":"2021","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.bbmt.2007.05.001","article-title":"Bronchiolitis Obliterans Syndrome (BOS), Bronchiolitis Obliterans Organizing Pneumonia (BOOP), and Other Late-Onset Noninfectious Pulmonary Complications following Allogeneic Hematopoietic Stem Cell Transplantation","volume":"13","author":"Yoshihara","year":"2007","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1200\/JCO.2016.68.8457","article-title":"Morbidity and Mortality Differences Between Hematopoietic Cell Transplantation Survivors and Other Cancer Survivors","volume":"35","author":"Chow","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1038\/s41409-020-0806-8","article-title":"Occurrence of long-term effects after hematopoietic stem cell transplantation in children affected by acute leukemia receiving either busulfan or total body irradiation: Results of an AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) retrospective study","volume":"55","author":"Saglio","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3324\/haematol.2016.150250","article-title":"Late effects of blood and marrow transplantation","volume":"102","author":"Inamoto","year":"2017","journal-title":"Haematologica"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ccm.2017.07.003","article-title":"Bronchiolitis Obliterans Syndrome and Other Late Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation","volume":"38","author":"Bergeron","year":"2017","journal-title":"Clin. Chest Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.bbmt.2011.09.013","article-title":"National Cancer Institute\u2013National Heart, Lung and Blood Institute\/Pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on Late Effects After Pediatric Hematopoietic Cell Transplantation: Long-Term Organ Damage and Dysfunction","volume":"17","author":"Nieder","year":"2011","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.bbmt.2010.11.018","article-title":"Bronchiolitis Obliterans Syndrome Epidemiology after Allogeneic Hematopoietic Cell Transplantation","volume":"17","author":"Au","year":"2011","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1182\/blood-2002-07-2231","article-title":"Nonmalignant late effects after allogeneic stem cell transplantation","volume":"101","author":"Salooja","year":"2003","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/sj.bmt.1705243","article-title":"Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: Joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT\/CIBMTR\/ASBMT)","volume":"37","author":"Rizzo","year":"2006","journal-title":"Bone Marrow Transplant."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1097\/MPH.0000000000001823","article-title":"Lung Function Predicts Outcome in Children with Obstructive Lung Disease after Hematopoietic Stem Cell Transplantation","volume":"43","author":"Kim","year":"2020","journal-title":"J. Pediatr. Hematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/ppul.24801","article-title":"Long-term pulmonary function testing in pediatric bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation","volume":"55","author":"Walther","year":"2020","journal-title":"Pediatr. Pulmonol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"106286","DOI":"10.1016\/j.rmed.2020.106286","article-title":"Updated prevalence, predictors and treatment outcomes for bronchiolitis obliterans syndrome after allogeneic stem cell transplantation","volume":"177","author":"Pham","year":"2020","journal-title":"Respir. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1182\/blood-2002-06-1813","article-title":"Association between acute and chronic graft-versus-host disease and bronchiolitis obliterans organizing pneumonia in recipients of hematopoietic stem cell transplants","volume":"102","author":"Freudenberger","year":"2003","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1046\/j.1365-2141.1998.00617.x","article-title":"Late-onset noninfectious pulmonary complications after allogeneic bone marrow transplantation","volume":"100","author":"Palmas","year":"1998","journal-title":"Br. J. Haematol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/sj.bmt.1704426","article-title":"Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation","volume":"33","author":"Patriarca","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1148\/rg.252045037","article-title":"Imaging Evaluation of Pulmonary and Abdominal Complications Following Hematopoietic Stem Cell Transplantation","volume":"25","author":"Coy","year":"2005","journal-title":"RadioGraphics"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.bmt.1703142","article-title":"Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation","volume":"28","author":"Afessa","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1378\/chest.10-2133","article-title":"Pulmonary Outcomes in Survivors of Childhood Cancer","volume":"140","author":"Huang","year":"2011","journal-title":"Chest"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0272-5231(03)00123-0","article-title":"Chemotherapy-induced lung disease","volume":"25","author":"Limper","year":"2004","journal-title":"Clin. Chest Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/08880010490272894","article-title":"Pulmonary Dysfunction in Pediatric Oncology Patients","volume":"21","author":"Meyer","year":"2004","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00001622-200107000-00006","article-title":"Radiation-induced and chemotherapy-induced pulmonary injury","volume":"13","author":"Abid","year":"2001","journal-title":"Curr. Opin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.bmt.1704549","article-title":"Effects of allogeneic bone marrow transplantation on pulmonary function in 80 children in a single paediatric centre","volume":"34","author":"Bruno","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"ref_104","first-page":"594","article-title":"Pulmonary function in long-term survivors of pediatric hematopoietic cell transplantation","volume":"47","author":"Mph","year":"2005","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/cncr.24897","article-title":"Pulmonary dysfunction in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem cell transplantation","volume":"116","author":"Inaba","year":"2010","journal-title":"Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/thx.54.2.131","article-title":"Late pulmonary sequelae after childhood bone marrow transplantation","volume":"54","author":"Cerveri","year":"1999","journal-title":"Thorax"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/(SICI)1099-0496(199907)28:1<31::AID-PPUL6>3.0.CO;2-J","article-title":"Respiratory function in children undergoing bone marrow transplantation","volume":"28","author":"Leneveu","year":"1999","journal-title":"Pediatr. Pulmonol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1046\/j.1365-2141.2001.02678.x","article-title":"Health and functional status of adult recipients 1 year after allogeneic haematopoietic stem cell transplantation","volume":"113","author":"Mary","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/pbc.20304","article-title":"Pulmonary function impairment in children following hematopoietic stem cell transplantation","volume":"45","author":"Wieringa","year":"2005","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/0284186X.2017.1406137","article-title":"Obstructive and restrictive pulmonary dysfunction in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation","volume":"57","author":"Stenehjem","year":"2017","journal-title":"Acta Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/petr.12313","article-title":"Pulmonary function following allogeneic stem cell transplantation in childhood: A retrospective cohort study of 51 patients","volume":"18","author":"Valjento","year":"2014","journal-title":"Pediatr. Transplant."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/INF.0b013e31823345e5","article-title":"Lethal Pulmonary Complications After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation","volume":"31","author":"Fazekas","year":"2012","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.rmed.2013.10.013","article-title":"Lung function and airway inflammation monitoring after hematopoietic stem cell transplantation","volume":"107","author":"Moermans","year":"2013","journal-title":"Respir. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-0609.2004.00366.x","article-title":"Relatively favorable outcomes of post-transplant pulmonary function in patients with chronic myeloid leukemia receiving non-myeloablative allogeneic hematopoietic stem cell transplantation","volume":"74","author":"Lee","year":"2005","journal-title":"Eur. J. Haematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.bbmt.2005.01.003","article-title":"Comparison of lung function after myeloablative and 2 Gy of total body irradiation-based regimens for hematopoietic stem cell transplantation","volume":"11","author":"Chien","year":"2005","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0140-6736(12)62114-X","article-title":"Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: A retrospective analysis","volume":"381","author":"Burt","year":"2013","journal-title":"Lancet"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/sj.bmt.1705782","article-title":"Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis","volume":"40","author":"Oyama","year":"2007","journal-title":"Bone Marrow Transplant."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2215\/CJN.08580719","article-title":"Acute Kidney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation","volume":"15","author":"Renaghan","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0272-6386(89)80054-X","article-title":"Acute Renal Failure Following Bone Marrow Transplantation: A Retrospective Study of 272 Patients","volume":"13","author":"Zager","year":"1989","journal-title":"Am. J. Kidney Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1053\/j.ajkd.2004.11.013","article-title":"Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation","volume":"45","author":"Parikh","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/j.1399-3046.2008.01069.x","article-title":"BK nephropathy in pediatric hematopoietic stem cell transplant recipients","volume":"13","author":"Verghese","year":"2009","journal-title":"Pediatr. Transplant."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bbmt.2005.06.001","article-title":"Blood and Marrow Transplant Clinical Trials Network Toxicity Committee Consensus Summary: Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation","volume":"11","author":"Ho","year":"2005","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/sj.bmt.1705573","article-title":"Chronic kidney disease in long-term survivors of hematopoietic cell transplant","volume":"39","author":"Hingorani","year":"2007","journal-title":"Bone Marrow Transplant."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.bbmt.2016.10.011","article-title":"Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation","volume":"23","author":"Clavert","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/imj.12216","article-title":"Diabetic ketoacidosis secondary to L-asparaginase in acute lymphoblastic leukaemia","volume":"43","author":"Gifford","year":"2013","journal-title":"Intern. Med. J."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.bbmt.2008.03.008","article-title":"Similar Risks for Chronic Kidney Disease in Long-Term Survivors of Myeloablative and Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation","volume":"14","author":"Cao","year":"2008","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1600-6143.2005.01131.x","article-title":"Chronic Kidney Disease Following Non-Myeloablative Hematopoietic Cell Transplantation","volume":"6","author":"Weiss","year":"2005","journal-title":"Am. J. Transplant."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/cncr.23773","article-title":"Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantation","volume":"113","author":"Choi","year":"2008","journal-title":"Cancer"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMra1404711","article-title":"Renal Complications of Hematopoietic-Cell Transplantation","volume":"374","author":"Hingorani","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.bbmt.2005.08.036","article-title":"The Importance of Age, Fludarabine, and Total Body Irradiation in the Incidence and Severity of Chronic Renal Failure after Allogeneic Hematopoietic Cell Transplantation","volume":"12","author":"Delgado","year":"2006","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/sj.bmt.1703312","article-title":"Renal function after autologous bone marrow transplantation in children: A long-term prospective study","volume":"29","author":"Frisk","year":"2002","journal-title":"Bone Marrow Transplant."},{"key":"ref_132","first-page":"569","article-title":"Cytomegalovirus infection and chronic graft-versus-host disease are significant predictors of renal failure after allogeneic hematopoietic stem cell transplantation","volume":"90","author":"Deconinck","year":"2005","journal-title":"Haematologica"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/sj.bmt.1705110","article-title":"Long-term renal function after hemopoietic stem cell transplantation in children","volume":"36","author":"Holthe","year":"2005","journal-title":"Bone Marrow Transplant."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.bbmt.2007.06.008","article-title":"Chronic Kidney Disease after Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation","volume":"13","author":"Kersting","year":"2007","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"434.e1","DOI":"10.1016\/j.jtct.2021.02.013","article-title":"Late Kidney Morbidity and Mortality in Hematopoietic Cell Transplant Survivors","volume":"27","author":"Wu","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.kint.2021.05.030","article-title":"Chronic kidney disease ten years after pediatric allogeneic hematopoietic stem cell transplantation","volume":"100","author":"Lugthart","year":"2021","journal-title":"Kidney Int."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1159\/000504354","article-title":"Risk Factors for Acute Kidney Injury and Chronic Kidney Disease following Allogeneic Hematopoietic Stem Cell Transplantation for Hematopoietic Malignancies","volume":"143","author":"Sakaguchi","year":"2019","journal-title":"Acta Haematol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/s41409-020-0843-3","article-title":"Impact of severe acute kidney injury and chronic kidney disease on allogeneic hematopoietic cell transplant recipients: A retrospective single center analysis","volume":"55","author":"Villarreal","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jtct.2021.02.030","article-title":"Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation","volume":"27","author":"Farhadfar","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1365-2141.2005.05728.x","article-title":"Nephrotic syndrome: An under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation","volume":"131","author":"Srinivasan","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1097\/01.tp.0000209496.26639.cb","article-title":"Nephrotic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation as a Late Complication of Chronic Graft-versus-Host Disease","volume":"81","author":"Colombo","year":"2006","journal-title":"Transplantation"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0002-9343(96)00407-X","article-title":"Natural History of Blood Pressure in Sickle Cell Disease: Risks for Stroke and Death Associated with Relative Hypertension in Sickle Cell Anemia","volume":"102","author":"Pegelow","year":"1997","journal-title":"Am. J. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1164\/rccm.201401-0065ST","article-title":"An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease","volume":"189","author":"Klings","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa1005565","article-title":"A Hemodynamic Study of Pulmonary Hypertension in Sickle Cell Disease","volume":"365","author":"Parent","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1164\/rccm.201207-1222OC","article-title":"Hemodynamic Predictors of Mortality in Adults with Sickle Cell Disease","volume":"187","author":"Mehari","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jacc.2006.09.038","article-title":"Diastolic Dysfunction Is an Independent Risk Factor for Death in Patients with Sickle Cell Disease","volume":"49","author":"Sachdev","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3324\/haematol.2016.153791","article-title":"Risk factors for mortality in adult patients with sickle cell disease: A meta-analysis of studies in North America and Europe","volume":"102","author":"Maitra","year":"2017","journal-title":"Haematologica"},{"key":"ref_148","first-page":"1999","article-title":"Increased Proportion of Sickle Cell Disease Patients Develop Cardiovascular Disease Risk Factors Following Successful Hematopoietic Cell Transplantation","volume":"130","author":"Stenger","year":"2017","journal-title":"Blood"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e28568","DOI":"10.1002\/pbc.28568","article-title":"Stable renal function in children and adolescents with sickle cell disease after nonmyeloablative hematopoietic stem cell transplantation","volume":"67","author":"Pedersen","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_150","first-page":"3271","article-title":"Development of a Multi-Center Cohort to Evaluate Long-Term Outcomes and Late Effects Following Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Initiative","volume":"130","author":"Stenger","year":"2017","journal-title":"Blood"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2019-128797","article-title":"Excellent Overall Survival and Low Incidence of Late Effects in Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Sickle Cell Disease: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR)","volume":"134","author":"Stenger","year":"2019","journal-title":"Blood"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.bbmt.2013.02.010","article-title":"Long-Term Outcome and Evaluation of Organ Function in Pediatric Patients Undergoing Haploidentical and Matched Related Hematopoietic Cell Transplantation for Sickle Cell Disease","volume":"19","author":"Dallas","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1038\/s41409-021-01298-7","article-title":"Stable to improved cardiac and pulmonary function in children with high-risk sickle cell disease following haploidentical stem cell transplantation","volume":"56","author":"Friedman","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1182\/bloodadvances.2019000387","article-title":"Reversal of a rheologic cardiomyopathy following hematopoietic stem cell transplantation for sickle cell disease","volume":"3","author":"Sachdev","year":"2019","journal-title":"Blood Adv."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00246-017-1764-9","article-title":"Changes in Bi-ventricular Function after Hematopoietic Stem Cell Transplant as Assessed by Speckle Tracking Echocardiography","volume":"39","author":"Covi","year":"2017","journal-title":"Pediatr. Cardiol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/bmt.2014.84","article-title":"Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease","volume":"49","author":"Bhatia","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1056\/NEJMoa035477","article-title":"Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease","volume":"350","author":"Gladwin","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cyto.2019.04.014","article-title":"Hypocholesterolemia and dysregulated production of angiopoietin-like proteins in sickle cell anemia patients","volume":"120","author":"Vendrame","year":"2019","journal-title":"Cytokine"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2015-05-644435","article-title":"Low forced expiratory volume is associated with earlier death in sickle cell anemia","volume":"126","author":"Kassim","year":"2015","journal-title":"Blood"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.bbmt.2009.10.005","article-title":"Pulmonary, Gonadal, and Central Nervous System Status after Bone Marrow Transplantation for Sickle Cell Disease","volume":"16","author":"Walters","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1055\/s-0033-1333754","article-title":"Normalized Transcranial Doppler Velocities, Stroke Prevention and Improved Pulmonary Function after Stem Cell Transplantation in Children with Sickle Cell Anemia","volume":"225","author":"Mynarek","year":"2013","journal-title":"Klin Padiatr."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.bbmt.2008.08.016","article-title":"Stable Long-Term Donor Engraftment following Reduced-Intensity Hematopoietic Cell Transplantation for Sickle Cell Disease","volume":"14","author":"Krishnamurti","year":"2008","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/ejh.12082","article-title":"Stem cell transplantation after reduced-intensity conditioning for sickle cell disease","volume":"90","author":"Lawitschka","year":"2013","journal-title":"Eur. J. Haematol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease","volume":"381","author":"Vichinsky","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A Phase 3 Trial ofl-Glutamine in Sickle Cell Disease","volume":"379","author":"Niihara","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/11\/3118\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:22:33Z","timestamp":1760138553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/11\/3118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":166,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["jcm11113118"],"URL":"https:\/\/doi.org\/10.3390\/jcm11113118","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,31]]}}}